Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Towards Organ Preservation and Cure Via Immunotherapy in Cutaneous Squamous Cell Carcinoma Patients, Normally Undergoing Morbid Curative Surgery and Radiotherapy. The MATISSE 2 Trial, an Investigator-initiated Multicentre Phase 2 Trial

NCT06823479 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06823479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06823479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Towards Organ Preservation and Cure Via Immunotherapy in Cutaneous Squamous Cell Carcinoma Patients, Normally Undergoing Morbid Curative Surgery and Radiotherapy. The MATISSE 2 Trial, an Investigator-initiated Multicentre Phase 2 Trial
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2025
Completion date
February 28, 2029
Enrollment
41 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell cancer, cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma (cscc), cutaneous squamous cell carcinoma of the head and neck